Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Aug 15;406(1):167-74.
doi: 10.1042/BJ20070296.

Naturally occurring and bioengineered apoA-I mutations that inhibit the conversion of discoidal to spherical HDL: the abnormal HDL phenotypes can be corrected by treatment with LCAT

Georgios Koukos  1 , Angeliki Chroni, Adelina Duka, Dimitris Kardassis, Vassilis I Zannis
Affiliations

Naturally occurring and bioengineered apoA-I mutations that inhibit the conversion of discoidal to spherical HDL: the abnormal HDL phenotypes can be corrected by treatment with LCAT

Georgios Koukos et al. Biochem J. .

Abstract

In the present study we have used adenovirus-mediated gene transfer of apoA-I (apolipoprotein A-I) mutants in apoA-I-/- mice to investigate how structural mutations in apoA-I affect the biogenesis and the plasma levels of HDL (high-density lipoprotein). The natural mutants apoA-I(R151C)Paris, apoA-I(R160L)Oslo and the bioengineered mutant apoA-I(R149A) were secreted efficiently from cells in culture. Their capacity to activate LCAT (lecithin:cholesterol acyltransferase) in vitro was greatly reduced, and their ability to promote ABCA1 (ATP-binding cassette transporter A1)-mediated cholesterol efflux was similar to that of WT (wild-type) apoA-I. Gene transfer of the three mutants in apoA-I-/- mice generated aberrant HDL phenotypes. The total plasma cholesterol of mice expressing the apoA-I(R160L)Oslo, apoA-I(R149A) and apoA-I(R151C)Paris mutants was reduced by 78, 59 and 61% and the apoA-I levels were reduced by 68, 64 and 55% respectively, as compared with mice expressing the WT apoA-I. The CE (cholesteryl ester)/TC (total cholesterol) ratio of HDL was decreased and the apoA-I was distributed in the HDL3 region. apoA-I(R160L)Oslo and apoA-I(R149A) promoted the formation of prebeta1 and alpha4-HDL subpopulations and gave a mixture of discoidal and spherical particles. apoA-I(R151C)Paris generated subpopulations of different sizes that migrate between prebeta and alpha-HDL and formed mostly spherical and a few discoidal particles. Simultaneous treatment of mice with adenovirus expressing any of the three mutants and human LCAT normalized plasma apoA-I, HDL cholesterol levels and the CE/TC ratio. It also led to the formation of spherical HDL particles consisting mostly of alpha-HDL subpopulations of larger size. The correction of the aberrant HDL phenotypes by treatment with LCAT suggests a potential therapeutic intervention for HDL abnormalities that result from specific mutations in apoA-I.

PubMed Disclaimer

Figures

Figure 1
Figure 1. apoA-I expression and in vitro functional assays
(A) SDS/PAGE analysis of 100 μl of culture medium of HTB13 cells infected with control adenovirus expressing GFP, adenovirus expressing WT or the mutants apoA-I(R151C)Paris, apoA-I(R160L)Oslo and apoA-I(R149A). apoA-I levels can be assessed qualitatively by comparison with the intensity of the band of a sample containing 1 μg of BSA. ‘M’ indicates protein markers. (B) Activation of LCAT by rHDL containing WT or mutant apoA-I forms. The apparent Km and Vmax values are given at the bottom of the Figure. The catalytic efficiency of the enzyme, expressed as the Vmax (app)/Km (app) ratio, is plotted and expressed as percentage of WT control. Values are the means±S.D. for three independent experiments performed in duplicate. (C) cAMP-dependent (ABCA1-mediated) cholesterol efflux from J774 murine macrophages in the presence of WT apoA-I, apoA-I(R151C)Paris, apoA-I(R160L)Oslo or apoA-I(R149A), as indicated, was determined as described in the Experimental section. Values are the means±S.D. for three independent experiments performed in duplicate.
Figure 2
Figure 2. FPLC profiles of TC in plasma of apoA-I−/− mice infected with 1×109 pfu of adenoviruses expressing the WT apoA-I, apoA-I(R151C)Paris, apoA-I(R160L)Oslo, apoA-I(R149A) or the control protein GFP
Plasma samples were obtained from mice infected with the recombinant adenoviruses, 4 days post-infection.
Figure 3
Figure 3. Analyses of plasma of apoA-I−/− mice infected with adenoviruses expressing the WT apoA-I (A, E, J), the apoA-I(R160L)Oslo (B, F, K), apoA-I(R149A) (C, G, L), the apoA-I(R151C)Paris (D, H, M) or the control adenovirus expressing GFP (I) by density-gradient ultracentrifugation, SDS/PAGE and two-dimensional gel electrophoresis
(A–C) SDS/PAGE analysis of density-gradient ultracentrifugation fractions. The densities of the fractions are indicated on the top of the Figure. (E–I) EM pictures of HDL fraction 6 obtained from apoA-I−/− mice expressing the WT apoA-I, the mutant forms or the control adenovirus expressing GFP, following density-gradient ultracentrifugation of plasma. The arrows indicate discoidal HDL particles. (J–M) Two-dimensional (2D) gel electrophoresis and Western-blot analysis of plasma obtained from mice infected with adenoviruses expressing the WT or the mutant forms of apoA-I, as indicated. The arrows indicate the different HDL subpopulations.
Figure 4
Figure 4. Analyses of plasma of apoA-I−/− mice infected with a combination of adenoviruses expressing human LCAT (5×108 pfu) and apoA-I(R160L)Oslo (1×109 pfu), apoA-I(R149A) (1×109 pfu) or apoA-I(R151C)Paris (1×109 pfu) mutants
(A–C) FPLC profiles of TC and comparison with the corresponding profiles of plasma obtained from apoA-I−/− mice expressing the WT apoA-I or each of the three apoA-I mutants alone, as indicated. The CE/TC ratio of HDL fractions 15–22 of the FPLC is indicated. (D–F) SDS/PAGE profiles of fractions obtained by density-gradient ultracentrifugation analysis of plasma of apoA-I−/− mice expressing the mutant forms of apoA-I in combination with the human LCAT, as indicated. (G–I) EM pictures of HDL fraction 6, following density-gradient ultracentrifugation of plasma obtained from apoA-I−/− mice expressing the indicated mutant forms in combination with human LCAT. (J–L) Two-dimensional gel electrophoresis and Western blot analysis of plasma obtained from mice infected with adenoviruses expressing the WT or the mutant forms of apoA-I, as indicated. The arrows indicate the different HDL subpopulations.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Zannis V. I., Kardassis D., Zanni E. E. Genetic mutations affecting human lipoproteins, their receptors and their enzymes. Adv. Hum. Genet. 1993;21:145–319. - PubMed
    1. Chroni A., Liu T., Gorshkova I., Kan H. Y., Uehara Y., von Eckardstein A., Zannis V. I. The central helices of apoA-I can promote ATP-binding cassette transporter A1 (ABCA1)-mediated lipid efflux. Amino acid residues 220-231 of the wild-type apoA-I are required for lipid efflux in vitro and high density lipoprotein formation in vivo. J. Biol. Chem. 2003;278:6719–6730. - PubMed
    1. Chroni A., Koukos G., Duka A., Zannis V. I. The carboxy-terminal region of apoA-I is required for the ABCA1-dependent formation of alpha-HDL but not prebeta-HDL particles in vivo. Biochemistry. 2007;46:5697–5708. - PMC - PubMed
    1. Laccotripe M., Makrides S. C., Jonas A., Zannis V. I. The carboxyl-terminal hydrophobic residues of apolipoprotein A-I affect its rate of phospholipid binding and its association with high density lipoprotein. J. Biol. Chem. 1997;272:17511–17522. - PubMed
    1. Liu T., Krieger M., Kan H. Y., Zannis V. I. The effects of mutations in helices 4 and 6 of apoA-I on scavenger receptor class B type I (SR-BI)-mediated cholesterol efflux suggest that formation of a productive complex between reconstituted high density lipoprotein and SR-BI is required for efficient lipid transport. J. Biol. Chem. 2002;277:21576–21584. - PubMed

Publication types

MeSH terms